# US 2022/0087971 A1 · Fap-activated therapeutic agents, and uses related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0087971 A1
- Document ID: US20220087971A1
- Status: Published application
- Kind: A1
- Application number: 17/330,848
- Filed: 2021-05-26
- Published: 2022-03-24
- Earliest claimed: 2014-06-13
- Assignees: Bach Biosciences, LLC
- Applicants: Bach Biosciences, LLC
- Inventors: William W. Bachovchin; Hung-sen Lai; David G. Sanford; Sarah E. Poplawski; Wengen Wu
- Web page: https://patentgrep.com/patent/US20220087971A1

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/69: Boron compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of treating a disorder characterized by fibroblast activation protein (FAP) upregulation, comprising administering to a subject in need thereof a therapeutically effective amount of a prodrug represented by the general formula:
or a pharmaceutically acceptable salt thereof, wherein:
R1 represents (C1-C10)alkyl, (C1-C10)alkoxy, (C1-C10)alkyl-C(O)—(C1-C10)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C10)alkyl, aryl, aryl(C1-C10)alkyl, heteroaryl, or heteroaryl(C1-C10)alkyl, wherein any R1 is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, carboxylate, cyano, amino, nitro, and thio (—SH); or —C(═X)R1 represents an N-terminally blocked alpha amino acid residue and X is O;
R2 represents H or a (C1-C6)alkyl;
R3 represents (C1-C6)alkyl;
R4 is absent or represents one, two or three substituents, each independently selected from the group consisting of a (C1-C6)alkyl, —OH, —NH2, or halogen;
X represents O or S;
Cyt′ represents a taxane; and
L represents a bond or a self-immolative linker which is metabolized after FAP cleavage of the prodrug to release the taxane
wherein the prodrug is selectively converted to the taxane by FAP+ stromal cells.

### Claim 12

A method of treating a disorder characterized by fibroblast activation protein (FAP) upregulation, comprising administering to a subject in need thereof a therapeutically effective amount of a prodrug represented by the general formula:
or a pharmaceutically acceptable salt thereof, wherein:
Cyt′ represents a taxane;
R1, taken together as —C(═X)R1, represents a moiety which at physiological pH reduces cell permeability of the prodrug relative to the taxane;
R2 represents H or a (C1-C6)alkyl;
R3 represents (C6-C6)alkyl;
R4 is absent or represents one, two or three substituents, each independently selected from the group consisting of a (C1-C6)alkyl, —OH, —NH2, or halogen;
X represents O or S; and
L represents a bond or a self-immolative linker which is metabolized after FAP cleavage of the prodrug to release the taxane;
wherein the prodrug is selectively converted to the taxane by FAP+ stromal cells.

### Claim 13 (depends on 11)

The method of claim 11, wherein the prodrug, or pharmaceutically acceptable salt thereof, is represented by the general formula:
R1 represents a heteroaryl moiety;
R2 represents H or a (C1-C6)alkyl;
Cyt′ represents a taxane; and
L represents a bond or a self-immolative linker which is metabolized after FAP cleavage of the prodrug to release the taxane;
wherein the prodrug is selectively converted to the cytotoxic compound or cytostatic compound by FAP+ stromal cells.

### Claim 14 (depends on 11)

The method of claim 11, wherein L is a self-immolative linker comprising a heterocycle.

### Claim 15 (depends on 14)

The method of claim 14, wherein the self-immolative linker is selected from the group consisting of His-Ala, p-aminobenzyloxycarbonyl (PABC), and 2,4-bis(hydroxymethyl)aniline.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 11)

The method of claim 11, wherein the disorder characterized by FAP upregulation is selected from the group consisting of cancer, fibrosis, and inflammation.

### Claim 19 (depends on 11)

The method of claim 11, wherein the disorder characterized by FAP upregulation is cancer.

### Claim 20 (depends on 11)

The method of claim 11, wherein the disorder characterized by FAP upregulation is fibrosis.

### Claim 21 (depends on 11)

The method of claim 11, wherein the disorder characterized by FAP upregulation is inflammation.

### Claim at position 13

22-26. (canceled)

### Claim 27 (depends on 19)

The method of claim 19, wherein the cancer is breast carcinoma.

### Claim 28 (depends on 19)

The method of claim 19, wherein the cancer is soft tissue sarcoma.

### Claim 29 (depends on 11)

The method of claim 11, wherein R2 is H.

### Claim 30 (depends on 11)

The method of claim 11, wherein R3 is methyl, ethyl, propyl, or isopropyl.

### Claim 31 (depends on 11)

The method of claim 11, wherein R3 is methyl.

### Claim 32 (depends on 11)

The method of claim 11, wherein R4 is absent or represents two halogens.

### Claim 33 (depends on 11)

The method of claim 11, wherein the taxane is selected from the group consisting of paclitaxel and docetaxel.

### Claim 34 (depends on 11)

The method of claim 11, wherein the prodrug has the formula:
or is a pharmaceutically acceptable salt thereof.
